Literature DB >> 27465568

PARS PLANA VITRECTOMY FOR LATE VITREORETINAL SEQUELAE OF INFECTIOUS ENDOPHTHALMITIS: Surgical Management and Outcomes.

Benjamin J Thomas1, Neesurg Mehta, Yoshihiro Yonekawa, Jayanth Sridhar, Ajay E Kuriyan, Nidhi Relhan, Michelle C Liang, Maria A Woodward, Andre J Witkin, Chirag Shah, Harry W Flynn, Sunir J Garg, Jeremy D Wolfe.   

Abstract

PURPOSE: To report the visual acuity outcomes after pars plana vitrectomy for delayed vitreoretinal sequelae of infectious endophthalmitis. All eyes were initially treated with intravitreal antibiotics (Abx).
METHODS: Multicenter, retrospective, consecutive case series.
RESULTS: Forty-two eyes met the study criteria. The mean follow-up was 48 weeks (SD ± 61.8). Mean interval from Abx to pars plana vitrectomy was 13 weeks (SD ± 14.3, range 2-70). Indications for pars plana vitrectomy included vitreous opacities (VO) (n = 22), epiretinal membrane (n = 9), and retinal detachment (n = 11). LogMAR visual acuity improved from 1.87 (Snellen equivalent: 20/1,482) preoperatively to 1.35 (Snellen equivalent: 20/447) at final evaluation (P < 0.001). LogMAR visual acuity improved significantly for patients with vitreous opacities (P < 0.01) and retinal detachment (P = 0.02) but not for patients with epiretinal membranes (P = 0.08).
CONCLUSION: Patients with infectious endophthalmitis can gain vision if they have a pars plana vitrectomy for delayed sequelae such as vitreous opacities or for retinal detachment.

Entities:  

Mesh:

Year:  2017        PMID: 27465568      PMCID: PMC5269601          DOI: 10.1097/IAE.0000000000001208

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  7 in total

Review 1.  Small-gauge pars plana vitrectomy: a report by the American Academy of Ophthalmology.

Authors:  Franco M Recchia; Ingrid U Scott; Gary C Brown; Melissa M Brown; Allen C Ho; Michael S Ip
Journal:  Ophthalmology       Date:  2010-09       Impact factor: 12.079

2.  Endophthalmitis After Intravitreal Injections: Incidence, Presentation, Management, and Visual Outcome.

Authors:  Andrzej Grzybowski
Journal:  Am J Ophthalmol       Date:  2015-08-01       Impact factor: 5.258

3.  Late surgical complications to endophthalmitis after cataract surgery in the post-EVS era.

Authors:  Søren Solborg Bjerrum; Jens F Kiilgaard; Morten La Cour
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-10-15       Impact factor: 3.117

4.  Additional procedures after the initial vitrectomy or tap-biopsy in the Endophthalmitis Vitrectomy Study.

Authors:  B H Doft; S F Kelsey; S R Wisniewski
Journal:  Ophthalmology       Date:  1998-04       Impact factor: 12.079

5.  Current Infectious Endophthalmitis Rates After Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents and Outcomes of Treatment.

Authors:  Ninel Z Gregori; Harry W Flynn; Stephen G Schwartz; Philip J Rosenfeld; Kamyar Vaziri; Andrew A Moshfeghi; Jorge A Fortun; Jaclyn L Kovach; Sander R Dubovy; Thomas A Albini; Janet L Davis; Audina M Berrocal; William E Smiddy
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2015-06       Impact factor: 1.300

6.  Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1995-12

Review 7.  Endophthalmitis: state of the art.

Authors:  Kamyar Vaziri; Stephen G Schwartz; Krishna Kishor; Harry W Flynn
Journal:  Clin Ophthalmol       Date:  2015-01-08
  7 in total
  3 in total

1.  The Malaysian cataract surgery registry: incidence and risk factors of postoperative infectious endophthalmitis over a 7-year period.

Authors:  Yong Zheng Wai; Lee Min Fiona Chew; Aziz Salowi Mohamad; Chai Liang Ang; Yong Yuin Chong; Tassha Hilda Adnan; Pik-Pin Goh
Journal:  Int J Ophthalmol       Date:  2018-10-18       Impact factor: 1.779

Review 2.  Review of Intraocular Pharmacokinetics of Anti-Infectives Commonly Used in the Treatment of Infectious Endophthalmitis.

Authors:  Andrea Luaces-Rodríguez; Miguel González-Barcia; María José Blanco-Teijeiro; María Gil-Martínez; Francisco Gonzalez; Francisco Gómez-Ulla; María-Jesús Lamas; Francisco-Javier Otero-Espinar; Anxo Fernández-Ferreiro
Journal:  Pharmaceutics       Date:  2018-05-29       Impact factor: 6.321

3.  Treatment outcomes of acute poptoperative infectious endophthalmitis.

Authors:  Kai-Ling Peng; Ya-Hsin Kung; Hui-Shuang Tsai; Tsung-Tien Wu
Journal:  BMC Ophthalmol       Date:  2021-10-29       Impact factor: 2.209

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.